throbber
United States Patent [19J
`Schiehser
`
`[54] FLUORINATED ESTERS OF RAPAMYCIN
`
`[75]
`
`Inventor: Guy A. Schiehser, Yardley, Pa.
`
`[73] Assignee: American Home Products
`Corporation, New York, N.Y.
`
`[21] Appl. No.: 682,793
`
`[22] Filed:
`
`Apr. 8, 1991
`
`Int. CI.s ..................... A61K 35174; C07D 491/14
`[51]
`[52] U.S. Cl ..................................... 514/183; 514/321;
`540/456
`[58] Field of Search ................. 540/456; 514/183, 321
`
`[56]
`
`References Cited
`U.S. PATENT DOCUMENTS
`3,929,992 12/1975 Sehgal et al ........................ 424/122
`3,993,749 11/1976 Sehgal et al. ....................... 424/122
`4,316,885 2/1982 Rakhit ................................. 424/122
`4,401,653 8/1983 Eng ..................................... 424/114
`4,650,803 3/1987 Stella et al. ........................... 546/90
`4,885,171 12/1989 Surendra et al. ................... 424/122
`
`OTHER PUBLICATIONS
`J. Antibiot. 28, 721-726, 727-732 (1975).
`J. Antibiot. 31, 539-545 (1978).
`Can. J. Physiol. Pharrnacol. 55, 48 (1977).
`FASEB 3, 3411, 5256 (1989).
`Lancet pp. 1183-1185 ( 1978).
`Med. Sci. Res. 17:877 (1989).
`
`Primary Examiner-Robert T. Bond
`Attorney. Agent, or Firm-Arnold S. Milowsky
`
`ABSTRACT
`[57]
`A compound of the structure
`
`I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
`US005100883A
`5,100,883
`[11] Patent Number:
`[45] Date of Patent: Mar. 31, 1992
`
`wherein
`RI and R2 are each, independently, hydrogen or
`
`R3 is a mono-, di-, poly-, or per-fluorinated alkyl
`group with the proviso that RI and R 2 are both not
`hydrogen, which by virtue of its immunosuppres(cid:173)
`sive activity is useful in treating transplantation
`rejection, host vs. graft disease, autoimmune dis(cid:173)
`eases and diseases of inflammation; by virtue of its
`antitumor activity is useful in treating solid tumors;
`and by virtue of its antifungal activity is useful in
`treating fungal infections.
`
`11 Claims, No Drawings
`
`Breckenridge Exhibit 1011
`Breckenridge v. Novartis AG
`
`

`
`1
`
`5,100,883
`
`2
`RI and R2 are each, independently, hydrogen or
`
`R 3 is a mono-, di-, poly-, or per-fluorinated alkyl
`group of 1-10 carbon atoms; with the proviso that
`RI and R2 are both not hydrogen.
`Of these compounds, preferred members are those in
`which R2 is hydrogen; those in which R3 is a mono-, di-,
`poly-, or per-fluorinated alkyl group of 1-6 carbon
`atoms; and those in which R2 is hydrogen and R3 is a
`mono-, di-, poly-, or per-fluorinated alkyl group of 1-6
`carbon atoms.
`The compounds of this invention acylated at the
`42-position can be prepared by acylating rapamycin
`with an acylating agent having the general structure
`
`0
`II
`XCR 3
`
`FLUORIJ'liATED ESTERS OF RAPAMYCIJlil
`
`10
`
`BACKGROUND OF THE INVENTION
`This invention relates to novel esters of rapamycin 5
`and a method for using them in the treatment of trans(cid:173)
`plantation rejection, host vs. graft disease, autoimmune
`diseases, diseases of inflammation, solid tumors, and
`fungal infections.
`Rapamycin is a macrocyclic triene antibiotic pro-
`duced by Streptomyces hygroscopicus, which was found
`to have antifungal activity, particularly against Candida
`albicans, both in vitro and in vivo [C. Vezina et al., J.
`Antibiot. 28, 721 (1975); S. N. Sehgai et al., J. Antibiot. 15
`28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539
`(1978); U.S. Pat. No. 3,929,992; and U.S. Pat. No.
`3,993,749].
`Rapamycin alone (U.S. Pat. No. 4,885,171) or in com(cid:173)
`bination with picibanil (U.S. Pat. No. 4,401,653) has 20
`been shown to have antitumor activity. R. Martel et al.
`[Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed
`that rapamycin is effective in the experimental allergic
`encephalomyelitis model, a model for multiple sclerosis;
`in the adjuvant arthritis model, a model for rheumatoid 25
`arthritis; and effectively inhibited the formation of IgE(cid:173)
`like antibodies.
`The immunosuppressive effects of rapamycin have
`been disclosed in F ASEB 3, 341 I ( 1989). Cyclosporin A
`and FK-506, other macrocyclic molecules, also have 30
`been shown to be effective as immunosuppressive
`agents, therefore useful in preventing transplant rejec(cid:173)
`tion [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989); and
`R. Y. Caine et al., Lancet 1183 (1978)].
`Mono- and diacylated derivatives of rapamycin (es- 35
`terified at the 28 and 43 positions) have been shown to
`be useful as antifungal agents (U.S. Pat. No. 4,316,885)
`and used to make water soluble prodrugs of rapamycin
`(U.S. Pat. No. 4,650,803). Recently, the numbering
`convention for rapamycin has been changed; therefore 40
`according to Chemical Abstracts nomenclature, the
`esters described above would be at the 31- and 42-posi(cid:173)
`tions.
`
`where X is OH, in the presence of a coupling reagent,
`such as CMC (l-cyclohexyl-3-(2-morpholinoethyl)car(cid:173)
`bodiimide metho-para-toluenesulphonate). The com-
`pounds of this invention also can be prepared by using
`an anhydride of the above described carboxylic acid as
`the acylating species. In addition, the acylating species
`can be an acid halide, where X can be Cl, Br, or I.
`Alternatively, reagents such as Ishikawa's Reagent
`(N,N-diethyl-1, 1-2,3,3,3-hexafluoropropylamine)
`can
`be used as an acylating reagent to give compounds of
`this invention.
`The compounds of this invention acylated at both the
`31- and 42-positions can be prepared by the methods
`described above by increasing variables such as reaction
`time, temperature, and quantity of acylating agent.
`The 31-acylated compounds of this invention can be
`prepared by protecting the 42-alcohol of rapamycin
`with a protecting group, such as with a tert-butyl dime(cid:173)
`thylsilyl group in the presence of a base, such as imidaz(cid:173)
`ole, followed by acylation of the 31-position with an
`acylating agent having the general structure shown
`45 above. Removal of the protecting group provides the
`31-acylated compounds. In the case of the tert-butyl
`dimethylsilyl protecting group, deprotection can be
`accomplished under mildly acidic conditions, such as
`with a mixture of aqueous acetic acid and THF.
`50 Having the 31-position acylated and the 42-position
`deprotected, the 42-position can be reacted with a dif(cid:173)
`ferent acylating agent than was reacted with the 31-
`alcohol, to give compounds having different acyl moi(cid:173)
`eties at the 31- and 42-positions. Alternatively, the 42-
`55 acyl compounds, prepared as described above, can be
`reacted with an acylating agent having a different struc(cid:173)
`ture to provide compounds having different acyl moi(cid:173)
`eties at the 31- and 42-positions.
`The acylating groups used to prepare the compounds
`60 of the invention are commercially available or can be
`prepared by methods that are disclosed in the literature.
`Immunosuppressive activity was evaluated in an in
`vitro standard pharmacological test procedure to mea(cid:173)
`sure lymphocyte proliferation (LAF) and in two in vivo
`65 standard pharmacological test procedures. The first in
`vivo procedure was a popliteal lymph node (PLN) test
`procedure which measured the effect of compounds of
`this invention on a mixed lymphocyte reaction and the
`
`DESCRIPTION OF THE INVENTION
`This invention provides derivatives of rapamycin
`which are useful as immunosuppressive, anti-inflamma-
`tory, and antifungal agents having the structure
`
`~OR 1
`
`-~~-OM'.
`~o
`
`0
`
`OMe
`
`wherein
`
`

`
`3
`second in vivo procedure evaluated the survival time of
`a pinch skin graft.
`The comitugen-induced thymocyte proliferation pro(cid:173)
`cedure (LAF) was used as an in vitro measure of the
`immunosuppressive effects of representative com- S
`pounds. Briefly, cells from the thymus of normal
`BALB/c mice are cultured for 72 hours with PHA and
`IL-1 and pulsed with tritiated thymidine during the last
`six hours. Cells are cultured with and without various
`concentrations of rapamycin, cyclosporin A, or test
`compound. Cells are harvested and incorporated radio(cid:173)
`activity is determined. Inhibition of lymphoprolifera(cid:173)
`tion is assessed as percent change in.counts per minute
`from non-drug treated controls. The results are ex- IS
`pressed by the following ratio, or as the percent inhibi(cid:173)
`tion of lymphoproliferation at 1 µM.
`
`5,100,883
`
`4
`The following table summarizes the results of repre(cid:173)
`sentative compounds of this invention in these three
`standard test procedures.
`TABLE 1
`PLN•
`LAP
`(ratio)
`(ratio)
`
`Compound
`
`Skin Graft
`(days+ SD)
`
`10
`
`Example I
`Example 2
`Example 3
`Example 4
`Rapamycin
`
`40
`2.3
`27
`14.8
`I
`
`1.28
`1.03
`0.23
`0.96
`I
`
`10.33 ::!:: 1.0
`12.0 ::!:: 1.3
`+
`+
`12.0 ::!:: 1.7
`
`•CaJculauon of rattos was described supra.
`;- Not evaluated
`
`3H-control thymus cells - Hl-rapamycin-treated thymus cells
`3H-control thymus cells - Hl·tcst compound-treated cells
`
`2S
`
`A mixed lymphocyte reaction (MLR) occurs when
`lymphoid cells from genetically distinct animals are
`combined in tissue culture. Each stimulates the other to
`undergo blast transformation which results in increased
`DNA synthesis that can be quantified by the incorpora(cid:173)
`tion oftritiated thymidine. Since stimulating a MLR is a
`function of disparity at Major Histocompatibility anti(cid:173)
`gens, an in vivo popliteal lymph node (PLN) test proce- 30
`dure closely correlates to host vs. graft disease. Briefly,
`irradiated spleen cells from BALB/c donors are in(cid:173)
`jected into the right hind foot pad of recipient C3H
`mice. The drug is given daily, p.o. from Day 0 to Day
`4. On Day 3 and Day 4, tritiated thymidine is given i.p., 3S
`b.i.d. On Day 5, the hind popliteal lymph nodes are
`removed and dissolved, and radioactivity counted. The
`corresponding left PLN serves as the control for the
`PLN from the injected hind foot. Percent suppression is
`calculated using the non-drug treated animals as allo- 40
`genie control. Rapamycin at a dose of 6 mg/kg, p.o.
`gave 86% suppression, whereas cyclosporin A at the
`same dose gave 43% suppression. Results are expressed
`by the following ratio:
`
`3H-PLN cells control C3H mouse -
`3H-~LN cells rapamycin-treated C3H mouse
`H-PLN cells control C3H mouse -
`lH-PLN cells test compound-treated C3H mouse
`
`The second in vivo test procedure is designed to
`determine the survival time of pinch skin graft from
`male DBA/2 donors transplanted to male BALB/c
`recipients. The method is adapt:d from Billingham R. SS
`E. and Medawar P. B, J. Exp. Biol. 28:385-402, (1951).
`Briefly, a pinch skin graft from the donor is grafted on
`the dorsum of the recipient as a bomograft, and an
`autograft is used as control in the same region. The
`recipients are treated with either varying concentra- 60
`tions of cyclosporin A as test control or the test com(cid:173)
`pound, intraperitoneally. Untreated recipients serve as
`rejection control. The graft is monitored daily and ob(cid:173)
`servations are recorded until the graft becomes dry and
`forms a blackened scab. This is considered as the rejec- 6S
`tion day. The mean graft survival time (number of
`days±S.D.) of the drug treatment group is compared
`with the control group.
`
`The results of these standard pharmacological test
`procedures demonstrate immunosuppressive activity
`both in vitro and in vivo for the compounds of this
`invention. Positive ratios in the LAF and PLN test
`procedures indicate suppression of T cell proliferation.
`20 As a transplanted pinch skin grafts are typically re(cid:173)
`jected within 6-7 days without the use of an immuno(cid:173)
`suppressive agent, the increased survival time of the
`skin graft when treated with the compounds of this
`invention further demonstrates their utility as immuno(cid:173)
`suppressive agents.
`Because the compounds of this invention are structur(cid:173)
`ally similar to rapamycin and have a similar activity
`profile to rapamycin, the compounds of this invention
`also are considered to have antitumor and antifungal
`activities.
`Based on the results of these standard pharmacologi(cid:173)
`cal test procedures, the compounds are useful in the
`treatment of transplantation rejection such as, heart,
`kidney, liver, bone marrow, and skin transplants; auto(cid:173)
`immune diseases such as, lupus, rheumatoid arthritis,
`diabetes mellitus, myasthenia gravis, and multiple scle-
`rosis; and diseases of inflammation such as, psoriasis,
`dermatitis, eczema, seborrhea, inflammatory bowel
`disease; solid tumors; and fungal infections.
`The compounds may be administered neat or with a
`pharmaceutical carrier to a mammal in need thereof.
`The pharmaceutical carrier may be solid or liquid.
`A solid carrier can include one or more substances
`which may also act as flavoring agents, lubricants, solu-
`4S bilizers, suspending agents, fillers, glidants, compression
`aids, binders or tablet-disintegrating agents; it can also
`be an encapsulating material. In powders, the carrier is
`a finely divided solid which is in admixture with the
`finely divided active ingredient. In tablets, the active
`SO ingredient is mixed with a carrier having the necessary
`compression properties in suitable proportions and
`compacted in the shape and size desired. The powders
`and tablets preferably contain up to 99% of the active
`ingredient. Suitable solid carriers include, for example,
`calcium phosphate, magnesium stearate, talc, sugars,
`lactose, dextrin, starch, gelatin, cellulose, methyl cellu-
`lose, sodium carboxymethyl cellulose, polyvinylpyr(cid:173)
`rolidine, low melting waxes and ion exchange resins.
`Liquid carriers are used in preparing solutions, sus(cid:173)
`pensions, emulsions, syrups, elixirs and pressurized
`compositions. The active ingredient can be dissolved or
`suspended in a pharmaceutically acceptable liquid car(cid:173)
`rier such as water, an organic solvent, a mixture of both
`or pharmaceutically acceptable oils or fats. The liquid
`carrier can contain other suitable pharmaceutical addi(cid:173)
`tives such as solubilizers, emulsifiers, buffers, preserva-
`tives, sweeteners, flavoring agents, suspending agents,
`thickening agents, colors, viscosity regulators, stabiliz-
`
`

`
`5,100,883
`
`0
`
`5
`6
`mg of dimethylaminopyridine and IOI mg (140 µI, 1
`ers or osmo-regulators. Suitable examples of liquid car-
`mmol) of triethylamine in 50 ml of methylene chloride
`riers for oral and parenteral administration include
`water (partially containing additives as above, e.g. eel-
`is treated dropwise with 114 mg (1 mmol, 77 µI) of
`trifluoroacetic acid. The mixture is maintained with
`Julose derivatives, preferably sodium carboxymethyl
`cellulose solution), alcohols (including monohydric 5 stirring for 17 h. An additional 1 mmol of CMC, 20 mg
`of dimethylaminopyridine, 1 mmol of triethylamine and
`alcohols and polyhydric alcohols, e.g. glycols) and their
`1 mmol of trifluoroacetic acid is added. Additional
`derivatives, and oils (e.g. fractionated coconut oil and
`arachis oil). For parenteral administration, the carrier
`trifluoroacetic acid (1 mmol) is added at 0.5 h intervals
`can also be an oily ester such as ethyl oleate and isopro-
`until conversion is complete.
`pyl myristate. Sterile liquid carriers are useful in sterile JO
`The mixture is diluted with water and ethyl ether and
`liquid form compositions for parenteral administration.
`is extracted with ethyl ether. The ethereal extract is
`The liquid carrier for pressurized compositions can be
`washed with water, 0.5N hydrochloric acid and finally
`halogenated hydrocarbon or other pharmaceutically
`with saturated aqueous sodium bicarbonate. The solu-
`acceptable propellent.
`.
`Liquid pharmaceutical compositions which are sterile
`tion is dried over magnesium sulfate, filtered and evapo-
`solutions or suspensions can be utilized by, for example, 15 rated to give 870 mg of a white foam. The crude prod-
`uct is subjected to flash chromatograph~ using hex-
`intramuscular, intraperitoneal or subcutaneous injec-
`tion. Sterile solutions can also be administered intrave-
`ane:ethyl ether (1 :4) as the eluant. The obtamed product
`nously. The compound can also be administered orally
`to af-
`is recrystallized fro~ hexane:cyclohexane !1:1)
`either in liquid or solid composition form.
`20 ford 397 mg of the title compound: m.p. 88 -91 C.
`Preferably, the pharmaceutical composition is in unit
`Anal. Calcd. for Cs3H78F3N014: C, 63.02; H, 7.78; N,
`1.39. Found: C, 63.21; H, 7.67; N, 1.34.
`dosage form, e.g. as tablets or capsules. In such form,
`the composition is sub-divided in unit dose containing
`The following representative compounds can be pre-
`appropriate quantities of the active ingredient; the unit
`pared from rapamycin and the appropriate carboxylic
`dosage forms can be packaged compositions, for exam- 25 acid by employing Method B used to prepare the title
`pie, packeted powders, vials, ampoules, prefilled syrin-
`compound in Example 1.
`ges or sachets containing liquids. The unit dosage form
`Rapamycin, 42-ester with perfluorovaleric acid
`can be, for example, a capsule or tablet itself, or it can be
`Rapamycin, 42-ester with perfluorodecanoic acid
`the appropriate number of any such compositions in
`Rapamycin, 42-ester with perfluorooctanoic acid
`package form. The dosage to be used in the treatment 30 Rapamycin, 42-ester with 9-H perfluorononanoic acid
`must be subjectively determined by the attending physi(cid:173)
`EXAMPLE2
`cian.
`In addition, the compounds of this invention may be
`Rapamycin, 42-ester with 2,3,3,3-tetrafluoropropanoic
`employed as a solution, cream, or lotion by formulation
`acid
`with pharmaceutically acceptable vehicles containing 35
`To a solution of 914 mg (1 mmol) of rapamycin in 20
`0.1-5 percent, preferably 2%, of active compound
`ml of methylene chloride is added 245 mg ( 1.1 mmol) of
`which may be administered to a fungally affected area.
`Ishikawa Reagent (N,N-diethyl 1,1,2,3,3,3-hexafluoro(cid:173)
`The following examples illustrate the preparation of
`propylamine). After 1 hr, an additional 84 mg (0.4
`representative compounds of this invention.
`mmol) of Ishikawa Reagent is added. The mixture is
`40 stirred for 2 h and then is diluted with ethyl ether and
`aqueous sodium bicarbonate. The ethyl ether layer is
`separated and the aqueous layer is reextracted with
`ethyl ether (2 times). The combined ethereal extracts
`are dried over magnesium sulfate, filtered and removed
`of solvent in vacuo to give 762 mg of a solid foam.
`A portion of the crude product is subjected to silica
`gel chromatography using hexane:ethyl ether (1 :4) as
`the eluant to give 310 mg of product (Rf=0.28 hex(cid:173)
`ane:ethyl ether(l :4)). Recrystallization from hexane:cy(cid:173)
`clohexane (3:1) gives, after high vacuum drying over
`phosphorus pentoxide, 246 mg of the title compound:
`m.p. 87° -90° C.;
`Anal. Calcd. for CS4ff79F.N014: C, 62.23; H, 7.64, N,
`1.34. Found: C, 62.97; H, 7.69; N, 1.07.
`
`EXAMPLE 1
`Rapamycin, 42-ester with trifluoroacetic acid
`Method A
`To a solution of 274 mg (0.3 mmol) of rapamycin in
`10 ml of methylene chloride is added 63 mg (0.3 mmol, 45
`43 µI) of trifluoroacetic anhydride and then 39 mg (0.3
`mmol) of diisopropylethylamine (Hunig's base). The
`mixture is stirred for 30 min and then an additional 78
`mg (0.6 mmol, 106 µl) ofHunig's base is added followed
`by 63 mg (43 µI, 0.3 mmol) oftrifluoroacetic anhydride. 50
`After 30 min the reaction mixture is diluted with
`ethyl ether and aqueous sodium bicarbonate. The mix(cid:173)
`ture is extracted with ethyl ether (3 times) and the com(cid:173)
`bined organic extracts are washed with aqueous sodium
`bicarbonate. The resulting extract is dried over magne- 55
`EXAMPLE 3
`sium sulfate and removed of solvent in vacuo to give a
`solid foam.
`Rapamycin, 42-ester with difluoroacetic acid
`Flash chromatography on silica gel using ethyl
`ether:hexane (4:1) as the eluant gave 96 mg of product
`A solution of914 mg (1 mmol) ofrapamycin, 846 mg
`which is recrystallized from cyclohexane:hexane (1:1) 60 (2mmol)ofCMC,40mgofdimethylaminopyridineand
`to give 68 mg of the title compound: m.p. 87°-91° C.
`202 mg (280 µI, 2 mmol) of triethylamine in 50 ml of
`Anal Calcd. for C53H7gF3N014: C, 63.02; H, 7.78; N,
`methylene chloride is treated dropwise with 192 mg
`1.39. Found: C, 62.85; H, 7.84; N, 1.41.
`(126 µl, 2 mmol) of difluoroacetic acid. The mixture is
`maintained with stirring for 1 h and additional triethyl-
`65 amine and difluoroacetic acid is added until the conver(cid:173)
`sion is complete.
`The mixture is diluted with water and ethyl ether and
`is extracted with ethyl ether. The ethereal extract is
`
`Method B
`A solution of914 mg (I mmol) ofrapamycin, 423 mg
`(I mmol) of CMC (l-cyclohexyl-3-(2-morpholinoe(cid:173)
`thyl)carbodiimide metho-para-toluenesulphonate), 20
`
`

`
`5,100,883
`
`7
`washed with water, 0.5N hydrochloric acid and finally
`with saturated aqueous sodium bicarbonate. The solu(cid:173)
`tion is dried over magnesium sulfate, filtered and evapo(cid:173)
`rated to give a white foam. The crude product is crys(cid:173)
`tallized from cyclohexane to give 703 mg product.
`Flash chromatography using hexane:ethyl ether(l :4) as
`the eluant followed by recrystallization from cyclohex(cid:173)
`ane affords the title compound: m.p. 87'-89' C.
`Anal. Calcd. for Cs3H79F2N014: C, 64.16; H, 8.03; N,
`1.41. Found: C, 64.46; H, 8.05; N, 1.42.
`
`8
`3. A compound of claim l where R3 is a mono-, di-,
`poly-, or per-fluorinated alkyl group of 1-6 carbon
`atoms.
`4. A compound of claim 1 where R2 is hydrogen and
`S R3 is a mono-, di-, poly-, or per-fluorinated alkyl group
`of 1-6 carbon atoms.
`S. A compound of claim 1 which is rapamycin, 42-
`ester with trifluoroacetic acid.
`6. A compound of claim 1 which is rapamycin, 42-
`10 ester with 2,3,3,3-tetrafluoropropanoic acid.
`7. A compound of claim 1 which is rapamycin, 42-
`ester with difluoroacetic acid.
`8. A compound of claim 1 which is rapamycin, 42-
`ester with pentafluoropropionic acid.
`9. A method of treating transplantation rejection,
`host vs. draft disease, autoimmune diseases, and diseases
`of inflammation in a mammal by administering an effec(cid:173)
`tive amount of a compound having the formula
`
`EXAMPLE4
`Rapamycin, 42-ester with pentafluoropropionic acid
`A solution of914 mg (l mmol) ofrapamycin, 846 mg IS
`(2 mmol) of CMC, 40 mg of dimethylaminopyridine and
`202 mg (280 µ.l, 2 mmol) of triethylamine in 50 ml of
`methylene chloride is treated dropwise with 328 mg
`(210 µ.I, 2 mmol) of pentafluoropropionic acid. The
`mixture is maintained with stirring for I h and addi- 20
`tional triethylamine and difluoroacetic acid is added
`until the conversion is complete.
`The mixture is diluted with water and ethyl ether and
`is extracted with ethyl ether. The ethereal extract is
`washed with water, 0.5N hydrochloric acid and finally 25
`with saturated aqueous sodium bicarbonate. The solu(cid:173)
`tion is dried over magnesium sulfate, filtered and evapo(cid:173)
`rated to give a white foam. The crude product is crys(cid:173)
`tallized from cyclohexane to give 703 mg product.
`Flash chromatography using hexane:ethyl ether (1:4) as 30
`the eluant followed by recrystallization from hexane:cy(cid:173)
`clohexane (1: 1) affords the title compound: m.p. 90' -97'
`c.
`Anal. Calcd. for CS4H78FsN014: C, 61.18; H, 7.42; N,
`1.32. Found: C, 61.45; H, 7.42; N, 1.33.
`What is claimed is:
`l. A compound of the formula
`
`3S
`
`wherein
`RI and R2 are each, independently, hydrogen or
`
`40
`
`4S
`
`so
`
`SS
`
`wherein
`RI and R2 are each, independently, hydrogen or
`
`R3 is a mono-, di-, poly-, or per-fluorinated alkyl
`group of 1-10 carbon atoms; with the proviso that
`RI and R2 are both not hydrogen.
`2. A compound of claim 1 where R2 is hydrogen.
`
`60 R3 is a mono-, di-, poly-, or per-fluorinated alkyl group
`of 1-10 carbon atoms; with the proviso that RI and R 2
`are both not hydrogen.
`10. A pharmaceutical composition for use as an im(cid:173)
`munosuppressive agent comprising an immunosuppres-
`6S sive amount of a compound of claim l.
`11. A composition as claimed in claim 10 in unit dos(cid:173)
`age form.
`• • • • •

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket